Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Newton Biocapital is a venture capital firm founded to leverage innovation in Europe and Japan, with offices in Brussels and Tokyo. The firm focuses on early-stage investments in life sciences, specifically targeting chronic health conditions. It manages a portfolio of 8 companies and emphasizes collaboration between European and Japanese ecosystems.
This firm invests in early-stage life sciences companies addressing chronic health conditions such as oncology, autoimmune, neurological, metabolic, and genetic diseases. Check sizes typically range from pre-seed to Series A funding. Newton Biocapital takes a hands-on approach, actively participating in strategic decisions and clinical programs of its portfolio companies.
Notable portfolio companies include SANTERO, developing first-in-class antibiotics for multi-drug resistant infections; Dim3, offering a clinical nutrition platform; Epics Therapeutics, focused on oncology drugs based on RNA epigenetics; and Synergia Medical, innovating neurostimulation devices for refractory epilepsy. Other companies include Acticor Biotech, Sequana Medical, EditForce, and J-Pharma.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.